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Efﬁcient delivery of stem cells to heart regions is still a major problem for cell therapy. Here, we report experiments aimed to
improve migration of mouse and human cardiacmesoangioblasts to the damaged heart. Cardiac mesoangioblasts were induced
to transmigrate through the endothelium by factors released by cardiomyocytes or cytokines, among which stromal-derived
factor 1 (SDF-1) was the most potent. Cardiac mesoangioblasts were also delivered into the left ventricular (LV) chamber of mice
aftercoronaryarteryligation(CAL), andtheir invivohoming tothe damagedheartwasfoundtobequitemodest.Pretreatmentof
cardiac mesoangioblasts with SDF-1 or transient expression of L-selectin induced a two- to three-fold increase in their
transmigration and homing to the damaged heart. Therefore, combined pretreatment with SDF-1 and L-selectin generated
modiﬁedcardiacmesoangioblasts,50%ofwhich,afterinjectionintotheLVchamberofmiceearlyafterCAL,homedirectlytothe
damaged free wall of the heart. Finally, modiﬁed mouse cardiac mesoangioblasts, injected into the LV chamber regenerate a
larger surface of the ventricle in long-term experiments in comparison with their control counterparts. This study deﬁnes the
requirements for efﬁcient homing of cardiac mesoangioblasts to the damaged heart and offers a new potent tool to optimize
efﬁciency of future cell therapy protocols for cardiovascular diseases.
Cell Death and Differentiation (2012) 19, 345–355; doi:10.1038/cdd.2011.110; published online 26 August 2011
Homing is the process by which cells reach a speciﬁc target
tissue through the general circulation. This mechanism has
been studied extensively both in vitro and in vivo with different
cell types, such as leukocytes or hematopoietic stem cells
1,2
and is believed to rely on adhesion molecules and cytokine
receptors, consisting of a rolling interaction with the endothe-
lium, followed by ﬁrm adhesion and transmigration into the
surrounding tissue.
3–5
The repertoire of cytokine expression by the target tissue
and expression of the relative receptors on endothelial cells
inﬂuence the efﬁciency of homing. During inﬂammation that
follows injury or disease, cytokines are involved not only in the
recruitment of leukocytes but also in that of circulating stem
cells.
6,7 In fact, stromal-derived factor (SDF-1) and VEGF
favor the arrest of progenitors on the vascular endothelium,
whereas interleukin-8 (IL-8) promotes stem cell mobilization
fromthebonemarrow.
8–10HMGB1andtumornecrosisfactor-
alpha (TNF-a) have also been described as signals that
induce migration of different mesenchymal cells.
11–13
Although these mechanisms have been elucidated to a large
extent for leukocytes, far less is known for the new types of
recently described stem cells and this limits the possibility of
their efﬁcient delivery to target tissues.
Cardiac mesoangioblasts were recently characterized as a
population of mesenchymal stem cells that differentiate
efﬁciently into cardiomyocytes (CMCs).
14,15 They have been
previously shown to restore to a signiﬁcant extent heart
structure and function in a mouse model of coronary artery
ligation (CAL).
14 One main reason for the partial effect of
cardiac mesoangioblasts in this model is likely to be ascribed
to the limited homing of these cells to the heart. Cardiac
mesoangioblast extravasation must be directed by selective
precursor-endothelial cell recognition.
To increase the efﬁciency of cardiac repair by cardiac
mesoangioblasts, it would be essential to increase their
homing and survival in the heart, with the additional beneﬁt of
reducing unspeciﬁc trapping in the capillary ﬁlters of the body.
To this aim, we investigated the role of some adhesion
molecules and cytokines in the transmigration of cardiac
mesoangioblasts in vitro through the endothelial monolayer
and in vivo, their migration in the infarct area of the heart in
mice whichunderwentpermanentCAL.
15 Here, wereportthat
expression of L-selectin and exposure of cells to SDF-1
improveuptoﬁve-foldthehomingofcardiacmesoangioblasts
to the infarcted free wall of the heart. We also show that this
treatment improves the recovery of the left ventricular (LV)
wall motion after infarction and the quantity of regenerated
myocardium. These results elucidate the homing mechanism
of cardiac mesoangioblasts and open a new opportunity for
improving efﬁcacy of cell therapy in cardiovascular diseases.
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Neonatal CMCs and SDF-1 favor cardiac mesoangioblast
transmigration in vitro. Cardiac mesoangioblasts were
starved for 12h in the absence of serum and then subjected
to transmigration assays using Transwell chambers. We
created an artiﬁcial environment in which cardiac
mesoangioblasts would face a TNF-a-activated endothelium
separating them from neonatal CMCs or speciﬁc cytokines. As
shown in Figure 1a, cardiac mesoangioblasts were unable to
cross endothelium-coated ﬁlters in the absence of stimuli.
However, neonatal CMCs in culture induced active migration
(sixfold above control) of cardiac mesoangioblasts but not of
primary ﬁbroblasts. This effect was slightly stronger than that
induced by ﬁbroblast growth factor (FGF), used as a positive
control. We also performed a chemotaxis assay through
endothelium-coated ﬁlters with a panel of cytokines. As shown
in Figure 1a, the presence of SDF-1 in the lower chamber
caused an eight-fold increase in mesoangioblast migration, a
signiﬁcantly more robust effect than that elicited by FGF,
MCP-1 or TNF-a, previously described as enhancers of
mesoangioblast migration.
13 Interestingly, when an
antagonist for CXCR4 (AMD3100) was used, CMC-induced
mesoangioblast migration was abolished by 40%
demonstrating a direct correlation between SDF-1-induced
signaling and migration of cardiac mesoangioblasts. Besides,
as shown in Figure 1b, SDF-1, MCP-1 and IL-8 were detected
at higher levels in the supernatant from CMCs than in
ﬁbroblasts. These data suggest that differentiated CMCs
may secrete cytokines such as SDF-1 or MCP-1 that favor
cardiac mesoangioblast transmigration by either a chemotactic
effect and/or by modifying the endothelium barrier.
Figure 1 Induction of cardiac mesoangioblast transmigration by cytokines in vitro.( a) Mouse cardiac mesoangioblasts or ﬁbroblasts were plated on endothelium-coated
Transwellﬁltersandinducedtomigratefor6hinpresenceofcardiomyocytes(CMCs)ordifferentcytokines(30ng/mlFGF;50ng/mlSDF-1;80ng/mlMCP-1;30ng/mlTNF-a;
10ng/ml AMD3100, CXCR4 antagonist). A representative out of ﬁve independent experiments run in duplicate is shown (left; *ao0.02). A representative image of the
transmigrated cardiacmesoangioblastsin thepresenceof CMCs, SDF-1or MCP-1isalso shown. Bar,30mm. (b)Supernatantsfromﬁbroblastsor CMCswerecollectedafter
4 days, and different cytokines were detected using the mouse multi-cytokine detection system. One out of three experiments is shown (*ao0.025)
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Cell Death and DifferentiationCardiac mesoangioblasts and homing in vivo to the
heart. A property of stem cells is their ability to migrate
through different routes. Clinical trials for cardiovascular
diseases have had modest success, possibly because of
inefﬁcient delivery of donor cells to the heart. To assess the
ability of cardiac mesoangioblasts to migrate in vivo,w e
injected 5 10
5 GFP-labeled cardiac mesoangioblasts into
the LV chamber of wild-type (WT) C57 mice and mice that
had undergone CAL few hours earlier. Mice were killed 6, 12
or 24h after injection; the heart (free wall) and ﬁlter organs
(such as the liver, spleen and lungs) were collected and RNA
was extracted. The percentage of migrated cardiac
mesoangioblasts in each recipient organ was calculated by
real-time PCR for GFP expression as a percentage of the
value corresponding to the total of injected cells. As shown in
Figure 2a, cardiac mesoangioblasts that migrated to the
heart in control mice (gray columns), were B5% of injected
cells, whereas most of the injected cells were retained in the
different ﬁlter organs, without reaching the heart.
Interestingly, the presence of an infarct in the CAL model
(black columns) induced an enhanced migration (twofold) of
cardiac mesoangioblasts to the infarct zone, compared with
their control counterparts. Most of the injected cells were
again retained in the ﬁlter organs, but this time B10% of
injected cells could reach the damaged area of the heart.
Similar results were obtained when real-time PCR was
performed for the y chromosome as double control
(Supplementary Figure S1a). We set our time of analysis at
6h after injection for the following in vivo experiments, as we
observed that the number of injected cells remains constant
for the ﬁrst 12h after the injection (Figure 2a). As shown in
Figure 2b, the higher concentration of SDF-1, Il-8 and MCP-1
in the free wall of hearts from CAL mice in comparison with
control mice could explain the preferential homing of cardiac
mesoangioblasts.
Pretreatment of cardiac mesoangioblasts with SDF-1
increases their migration. In an attempt to increase the
number of cardiac mesoangioblasts that home speciﬁcally to
the infarcted zone, we followed two approaches. First, we
pretreated cardiac mesoangioblasts with several cytokines
for 12h before challenging them in the Transwell assay. The
results, shown in Figure 3a, indicated that pretreatment with
SDF-1 increased cardiac mesoangioblast migration to the
same extent observed when the same cytokine was present
in the lower chamber. This pretreatment did not modify the
surface selection markers nor the differentiation proﬁle of the
cardiac mesoangioblasts described previously.
14 Therefore,
SDF-1-pretreated GFP-cardiac mesoangioblasts were
injected into the LV chamber of control WT or CAL mice,
and after 6h, the hearts and ﬁlter organs were collected and
analyzed by real-time PCR for the presence of GFP. As
shown in Figure 3b, SDF-1 increased about threefold the
homing of cardiac mesoangioblasts to the injured area of the
heart in mice that underwent CAL. Consistently, the number
of cardiac mesoangioblasts detected in the ﬁlter organs was
reduced to almost half of control.
We then attempted to identify the surface molecules
responsible for the changes observed in cardiac mesoangio-
blast migration after pretreatment with SDF-1. Therefore, we
performed a microarray analysis for 125 genes including
surface receptors (Figure 3c). Five genes were signiﬁcantly
modiﬁed after pretreatment of cardiac mesoangioblasts with
SDF-1:MMP-2,MMP-9,CD44,caveolin-1andItgav.Toverify
the role of those molecules in cardiac mesoangioblast
transmigration, we repeated the Transwell assay in the
presence of antibodies (Abs) against CD44 or av-integrin,
metaloproteinase (MMP) inhibitor GM1489 or caveolin-1
(cav-1) small-interference RNA (siRNA) (Figure 3d). As
shown in Figure 3d, Abs against CD44 or cav-1 siRNA
signiﬁcantly inhibited SDF-1-induced in vitro transmigration.
Blocking MMPs’ activity with GM1489 slightly inhibited
transmigration induced by SDF-1.
Taken together, these data suggest that SDF-1 increases
cardiacmesoangioblasttransmigrationinvitroandhomingtothe
heart in vivo by increasing expression of several molecules
among which CD44 seems to be preferentially expressed.
L-selectin is necessary for efﬁcient cardiac
mesoangioblast transmigration and homing to the
heart. As revealed by microarray analysis (Tagliaﬁco E
Figure 2 Homing of cardiac mesoangioblasts in vivo.( a) Cardiac mesoangio-
blasts were injected into the LV chamber of mice subjected to coronary artery
ligation (CAL) or control mice. After 6, 12 or 24h, the heart and ﬁlter organs were
collected and the number of migrated cells was calculated by real-time PCR for
GFP. A mean of three independent experiments run in triplicate is shown
(*ao0.03). (b) Myocardium free walls of the hearts from 2-month-old WT or CAL
mice were homogenized and analyzed for cytokine expression using the mouse
multi-cytokine detection system. Concentrations have been normalized to protein
load. One out of three experiments is shown (*ao0.025)
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Cell Death and Differentiationand Cossu G, unpublished data), cardiac mesoangioblasts
do not express some of the key molecules that control rolling
and extravasation of leukocytes, such as L-selectin or b2
integrin.
1,5 Therefore, we transduced mesoangioblasts with
vectors expressing these molecules and also enhanced
green ﬂuorescence protein (EGFP) that were used
previously by our group.
13 These constructs did not modify
the surface expression markers nor the differentiation proﬁle
of the cardiac mesoangioblasts described previously.
14 To
assess whether the expression of these molecules could
improve cardiac mesoangioblast migration, cells transfected
with one or both constructs were subjected to transmigration
in vitro assay through the activated endothelium. As shown in
Figure 4a, L-selectin expression increased by six- to eight-
fold cardiac mesoangioblast transmigration, whereas b2
integrin expression increased only by twofold their
migration. Co-transfection of both constructs had no
statistically signiﬁcant cumulative effect (Figure 4a). When
L-selectin-expressing cardiac mesoangioblasts were injected
into the LV chamber of mice early after CAL, the number of
cells that reached the free wall of the heart increased
approximately twofold in different mice (Figure 4b).
Consistent with in vitro results, we did not observe any
cumulative effect with co-transfection of L-selectin and b2
integrin. Therefore, expression of L-selectin by cardiac
mesoangioblasts improves their migration and homing
possibly by favoring their interaction with ligands expressed
on the endothelium surface.
Pretreatment with SDF-1 of L-selectin-expressing
cardiac mesoangioblasts increased by ﬁvefold their
homing to the heart. We then tested the possibility of
additive or synergistic effects of the two approaches shown
above. Cardiac mesoangioblasts previously transfected with
L-selectin constructs were pretreated for 12h with SDF-1 and
then subjected to transmigration assay through the
endothelium. As shown in Figure 4c, the combination of
SDF-1 pretreatment and L-selectin expression seemed to
have a slightly synergistic effect and improved cardiac
mesoangioblast transmigration in vitro 15-fold more
efﬁciently than control. Therefore, these cells were injected
into the LV chamber of infarcted mice. As shown in
Figure 4d, results showed that almost 50% of injected cells
reached the injured myocardium of the heart after 6h, with
a concomitant reduction in the number of cardiac
mesoangioblasts detected in ﬁlter organs (Figure 4d).
Again, SDF-1 pretreatment and L-selectin expression
demonstrated a clear synergistic effect in in vivo
experiments. Similar results were obtained when real-time
PCR was performed for the y chromosome as double control
(Supplementary Figure S1b).
Myocardium regeneration after long-term treatment with
modiﬁed cardiac mesoangioblasts. Finally, to assess the
ability of modiﬁed cardiac mesoangioblasts not only to
migrate in vivo to the heart but also to regenerate the
myocardium, we injected 5 10
5 GFP-labeled control or
Figure 3 SDF-1 improves cardiac mesoangioblast migration through CD44, MMPs and cav-1. (a) Cardiac mesoangioblasts pretreated with different cytokines (50ng/ml
IL8 and SDF-1; 80ng/ml MCP-1; 30ng/ml TNF-a; 30ng/ml FGF) were plated on endothelium-coated ﬁlters and induced to migrate for 6h in the presence of mature
cardiomyocytes in the lower chamber. FGF was used as a positive control. One representative out of ﬁve independent experiments run in duplicate is shown (left; *ao0.01).
A representative image of the transmigrated SDF-1-pretreated cardiac mesoangioblasts is also shown (right). Bar, 30mm. (b) GFP-cardiac mesoangioblasts pretreated with
50ng/ml SDF-1 were injected into the LV chamber of control or CAL mice, and after 6h, the heart and ﬁlter organs were analyzed by real-time PCR for the presence of
migrated cells (*ao0.03,
þao0.02). (c) A gene array containing oligos corresponding to different mouse adhesion molecules was hybridized with cDNAs probes
retrotranscribed from RNA of cardiac mesoangioblasts pretreated with SDF-1. Relative RNA levels of selected mRNAs normalized to b-actin expression are shown. Data
presentedarethemeanoftwoindependentexperiments(*ao0.01).(d)SDF-1-pretreatedcardiacmesoangioblastswereincubatedwiththeMMPinhibitor,GM1489orsiRNA
cav-1inhibitororwithAbsagainstCD44andavintegrinandinducedtomigratefor6hthroughendothelium-coatedﬁltersandinthepresenceofmaturecardiomyocytesinthe
lower chamber. A representative out of three independent experiments run in duplicate is shown (*ao0.02,
þao0.005)
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Cell Death and Differentiationmodiﬁed (SDF-1 plus L-selectin) cardiac mesoangioblasts
into the LV chamber of C57 mice that underwent CAL. Mice
were then killed 6 weeks after injection, and the heart (free
wall) and ﬁlter organs (such as the liver, spleen and lungs)
were harvested and RNA was extracted. The percentage of
migrated and survived cardiac mesoangioblasts in each
recipient organ (engraftment) was calculated by real-time
PCR for GFP expression as a percentage of the value
corresponding to the total of injected cells, normalized to their
respective sham. As shown in Figure 5a, B10% of control-
injected cells were found in the heart after 6 weeks, whereas
435% of injected modiﬁed cardiac mesoangioblasts were
found in the same region. Similar results were obtained when
real-time PCR was performed for the y chromosome as
double control (Supplementary Figure S1c). To further verify
these percentages, the GFP-positive population was sorted
from digested hearts that had been injected 6 weeks before
with control or treated cells. As shown in Figure 5b, the
GFP-positive population was two times more abundant in the
case of pretreated cells (SDF-1 plus L-selectin) than with
control cells. As shown in Figure 5c, control cardiac
mesoangioblasts remained mainly in the ventricle wall (see
arrowheads), whereas modiﬁed cardiac mesoangioblasts
colonized larger areas inside the myocardium. Interestingly,
these modiﬁed GFP-cardiac mesoangioblasts could also
differentiate into new CMCs expressing sarcomeric actin 6
weeks after injection and therefore regenerate the damaged
tissue (Figures 5d and e and Supplementary Figure S2).
In fact, protein extraction from CAL-injected hearts conﬁrmed
the presence of injected GFP-cardiac mesoangioblasts
inside the ventricle; it was found that the quantity of
modiﬁed cardiac mesoangioblasts was higher after 6 weeks
than the number of control mesoangioblasts (Figure 5f). It is
noteworthy that GFP-cardiac mesoangioblasts isolated from
the free wall of the myocardium also expressed the
sarcomeric actin protein 6 weeks after injection as
analyzed by western blot (Figure 5f, lower panel), as well
as late cardiac differentiation genes analyzed by real-time
PCR (Figure 5g). Finally, before killing mice, we performed
echocardiography studies that revealed a slight improvement
in ventricular wall thickness, a two-fold increase of ejection
and shortening fraction (SF), as well as minor changes in LV
chamber diameter, 6 weeks after modiﬁed (SDF-1þ
L-selectin) cardiac mesoangioblasts injection (Table 1).
Therefore, the combined treatment of cardiac mesoangio-
blastswithSDF-1and L-selectinincreasesthequantityofcells
that arrive to the damaged heart and improves the myocar-
dium structure to a varying extent.
Human cardiac mesoangioblast migration to the heart
is also susceptible of being regulated by SDF-1
pretreatment and L-selectin expression. To test whether
a similar protocol would be also suitable for human cells, we
used human cardiac mesoangioblasts that have been
Figure 4 L-selectin increases cardiac mesoangioblast migration and has synergistic effects with SDF-1 pretreatment. (a) Cardiac mesoangioblasts transfected with
one or two vectors expressing different surface molecules and EGFP were plated on endothelium-coated ﬁlters and induced to migrate for 6h in the presence of mature
cardiomyocytes in the lower chamber. A representative out of ﬁve independent experiments run in duplicate is shown (left panel) (left; *ao0.01). A representative
image of the transmigrated cardiac mesoangioblasts transfected with L-selectin is also shown (right). Bar, 30mm. (b) Cardiac mesoangioblasts transfected with vectors
expressing L-selectin and/or b2-integrin and GFP were injected into the LV chamber of CAL mice, and after 6h, the heart and ﬁlter organs were collected. Percentage
ofmigratedcellswascalculatedafterperformingreal-timePCRforGFP.A meanof threeindependentexperimentsrunin triplicateisshown(*ao0.02).(c)SDF-1-pretreated
cardiac mesoangioblasts, transfected or not with vectors expressing L-selectin and GFP, were induced to migrate for 6h through endothelium-coated ﬁlters and in
the presence of mature cardiomyocytes in the lower chamber. A mean of three independent experiments run in duplicate is shown (left; *ao0.01). A representative image
of the transmigrated SDF-1-pretreated cardiac mesoangioblasts transfected with L-selectin is also shown (right). Bar, 30mm. (d) SDF-1-pretreated cardiac mesoangioblasts,
transfected or not with vectors expressing L-selectin-EGFP, as well as control cardiac mesoangioblasts were injected into the LV chamber of CAL mice, and after 6h, the
heart and ﬁlter organs were collected and analyzed by real-time PCR for the presence of GFP. A mean of six independent experiments run in triplicate is shown
(*ao0.01)
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Cell Death and Differentiationdescribed before to reconstitute the myocardium after
injection into SCID mice.
15 They have morphology and
gene expression similar to their mouse counterparts, a ﬁnite
lifespan and the ability to differentiate into CMCs. Human
cardiac mesoangioblasts were serum starved and then
subjected to transmigration assays using Transwell
chambers.
As shown in Figure 6a, human cardiac mesoangioblasts
were also unable to cross endothelium-coated ﬁlters in the
absenceofstimuli.However,matureCMCsorpretreatmentof
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Cell Death and Differentiationcells with SDF-1 induced from ﬁve- to eight-fold human
cardiac mesoangioblast migration.
We then transfected human cardiac mesoangioblasts (that
also do not express these molecules; Tagliaﬁco E and Cossu
G, unpublished observations) with vectors expressing
L-selectin and, after transfection, selected GFP-positive cells.
As shown in Figure 6a (right column), SDF-1 pretreatment
of L-selectin-expressing human cardiac mesoangioblasts
increased threefold their ability to cross the endothelial barrier
in Transwell assays. We then tested whether these in vitro
results could be translated into an animal model for infarction.
Therefore, human cardiac mesoangioblasts pretreated with
SDF-1 and transfected with vectors encoding L-selectin
were injected into the LV chamber of CAL-SCID mice that
do not reject human cells. As shown in Figure 6b, almost
45% of human-modiﬁed (SDF-1-pretreated and L-selectin-
transfected) cardiac mesoangioblasts reached the infarcted
free wall of the heart, 6h after injection into the LV chamber,
with a concomitant reduction in the number of cells detected
in ﬁlter organs.
Taken together, these data show that it is possible to
increase homing to the damaged area of the heart of human
cardiac mesoangioblasts with an experimental protocol
similar to that developed for mouse cardiac mesoangioblasts.
Discussion
Ischemic heart disease is today the major cause of cardiac
failure, and thus is a leading cause of death worldwide. Cell
therapy protocols, using different types of stem cells, have
achieved partial success.
16–21 Until now, intravascular or
intra-myocardialdeliveryofstemcellstotheheartseemedthe
most promising because of a partial but signiﬁcant restoration
of cardiac muscle structure and function. However, the
migration and differentiation potency of stem cells, as well
as their ability for regeneration are technical issues that have
to be solved. In this work, we provide a new experimental
strategy, based on pretreatment of donor cells with cytokines
and surface expression of certain adhesion molecules,
which improves homing of cardiac mesoangioblasts to the
damaged heart.
Testing cardiac mesoangioblast-migratory activity
in vitro. We initially measured cardiac mesoangioblast
migration with a Transwell assay, already proven as a
reliable indicator of the mechanisms that govern cellular
trafﬁcking in vivo.
22 Cardiac mesoangioblasts cross the
endothelium and migrate towards mature CMCs, an in vitro
setting mimicking the microenvironment. Likely, some factors
secreted by these mature CMCs stimulate cardiac
mesoangioblast migration as it has been demonstrated for
other cell types.
23–25 Microarray analysis had also shown that
cardiac mesoangioblasts express several receptors for
cytokines and therefore may respond to factors released by
inﬂammatory cells or CMCs during myocardial infarction.
Indeed, we found that SDF-1 was the most potent inducer of
cardiac mesoangioblast migration, more than TNF-a,
previously described as a chemoattractant for skeletal
muscle mesoangioblasts
13 or for mesenchymal adipose
stem cells.
11 SDF-1 has previously been described to be
present in the infarcted area.
10
Cardiac mesoangioblasts homing to cardiac tissue
in vivo. Homing to cardiac tissues in vivo proceeds
through multiple mechanisms. When WT cardiac
mesoangioblasts were injected into the LV chamber of the
heart in infarcted or WT mice, only a small percentage of
injected cells reached the injured myocardium, whereas most
cells ended trapped in ﬁlter organs. Interestingly, the
percentage of donor cells that could be recovered from the
infarcted zone of the heart was signiﬁcantly higher than that
from the spared myocardium or from control hearts, possibly
linked to the different cytokines pattern expressions in CMCs
exposed to ischemic injury.
26–28 In fact, when injected into
Figure5 Pretreatmentofmousecardiacmesoangioblastsincreasesmyocardiumregeneration.(a)Infarctedhearts,injectedwithcardiacmesoangioblastspretreatedwith
SDF-1andtransfectedwith the L-selectin-EGFPvectororwithcontrolcardiacmesoangioblasts,werecollectedafter6weeksandsubjectedto real-timePCRforthepresence
ofGFP.Ameanofsevenindependentexperimentsrunintriplicateisshown(*ao0.02).(b)Infarctedhearts,injectedwithcardiacmesoangioblastspretreatedwithSDF-1and
transfected with the L-selectin-EGFP vector or with control cardiac mesoangioblasts, were collected after 6 weeks and sorted for the GFP population after digestion.
A representative plot of four independent experiments is shown. (c) Immunostaining of the free wall collected 6 weeks after injection with control cardiac mesoangioblasts or
with cardiac mesoangioblasts pretreated with SDF-1 and transfected with the L-selectin-EGFP vector. Laminin is shown in red. Nuclei are stained with Hoechst (blue).
Magniﬁcation:  450. Scale bar, 100mm. (d) Immunoﬂuorescence for GFP and sarcomeric actin (red) from a heart region of CAL mice 6 weeks after injection with cardiac
mesoangioblastspretreatedwithSDF-1andtransfectedwith L-selectin-EGFP.Scalebar,100mm.(e)HighermagniﬁcationimmunoﬂuorescenceforGFPandsarcomericactin
(red) from the hearts of CAL mice 6 weeks after injection with cardiac mesoangioblasts pretreated with SDF-1 and transfected with L-selectin-EGFP. Nuclei are stained with
Hoechst (blue). Scale bar, 20mm. (f) Western blot for GFP and sarcomeric actin of total GFP-sorted fractions recovered from the hearts of CAL mice 6 weeks after injection
with control GFP-cardiac mesoangioblasts or with cardiac mesoangioblasts pretreated with SDF-1 and transfected with the L-selectin-EGFP vector. One representative out of
ﬁveindependentexperiments isshown. (g) Real-timePCRfor late cardiacdifferentiation genes on maturecardiomyocytes and GFP-sortedfractioncoming from thehearts of
CAL mice 6 weeks after injection with cardiac mesoangioblasts, both control or pretreated with SDF-1 and transfected with the L-selectin-EGFP vector. Quantities have been
normalized. A mean of four independent experiments run in triplicate is shown
Table 1 Ecocardiography values of the hearts coming from mice 6 weeks after
injection of control or cardiac mesoangioblasts transfected with L-selectin and
pretreated with SDF-1
PBS
Cardiac
precursors
SDF-1+
L-selectin
cardiac
precursors
P-value
Treated
cardiac
precursors
n¼8 n¼8 n¼6 versus PBS
LVIDd (mm) 4.32 4.73 4.89 0.43
EF (%) 27.12 34.28 41.17 0.032
FS (%) 17.65 25.47 33.10 0.0204
LVAWThd (mm) 0.49 0.60 0.72 0.0415
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Cell Death and Differentiationthe LV chamber, cardiac mesoangioblasts accumulate in the
ﬁrst capillary ﬁlter they encounter and migrate outside the
vessel, but only in the presence of inﬂammation, as in the
case of infarcted heart. Indeed, cardiac mesoangioblasts
express many receptors for inﬂammatory cytokines and
migrate in vitro and in vivo in response to different stimuli.
Enhancing cardiac mesoangioblast-migratory activity. Pre-
vious work had shown that HMGB-1 or TNF-a stimulates
proliferation and migration of skeletal muscle mesoangioblasts to
dystrophic muscle.
12,13 A si nt h ec a s eo fs k e l e t a lm u s c l e
mesoangioblasts, we hypothesized that different stem cells
would use different cytokine receptors for homing to the tissue of
interest. In the case of cardiac mesoangioblasts, we observed
that SDF-1 was the most potent molecule as chemoattractant.
Interestingly, our work shows that pretreatment of donor
cells with this cytokine is sufﬁcient to increase expression of
certain surface proteins necessary for migration and
extravasation. We further investigated the mechanisms
involved in this migration increment through a low-density array
performed with cardiac mesoangioblasts pretreated with SDF-1.
This experiment revealed that SDF-1 acts through CD44, a
molecule that has been described to help in the rolling and
extravasation of inﬂammatory cells.
29,30 However, cardiac
mesoangioblasts do not normally express many of these
leukocytes molecules required for an efﬁcient arrest at blood
Figure 6 Pretreatment of human cardiac mesoangioblasts also improves homing to the heart. (a) Human cardiac mesoangioblasts pretreated with SDF-1 or transfected
with L-selectin construction were plated on endothelium-coated ﬁlters and induced to migrate for 6h in the presence of cardiomyocytes. One representative out of three
independent experiments run in duplicate is shown. (left; *ao0.02,
þao0.01). A representative image of the transmigrated SDF-1-pretreated cardiac mesoangioblasts
transfectedornotwith L-selectinisalsoshown(right).Bar,30mm. (b)Humancardiacmesoangioblaststransfectedwithvectorsexpressing L-selectinandGFPandpretreated
with SDF-1 were injected into the LV chamber of CAL-SCID mice, and after 6h, the heart and ﬁlter organs were collected. The percentage of migratedcells is calculatedafter
performing real-time PCR for GFP with the different samples. A mean of ﬁve independent experiments run in triplicate is shown (*ao0.025,
þao0.015)
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bind efﬁciently and are ﬁnally trapped inside ﬁlter organs.
Therefore, L-selectin and b2 integrin were expressed in cardiac
mesoangioblasts to study their migration ability. The expression
of L-selectin resulted in an eight-fold increase in cardiac
mesoangioblast transmigration in vitro, and the number of cells
that reached the damaged area was also doubled in vivo,
reducing their number in ﬁlter organs. The combined strategies
(i.e., pretreatment with SDF-1 of cardiac mesoangioblasts
expressing L-selectin) resulted in a 15-fold increment of
transmigration through the endothelium in vitro and 5-fold
enhanced migration in vivo. Finally, we demonstrate that
modiﬁed cardiac mesoangioblasts are not only able to reach
the heart but also to colonize large areas of the myocardium
where they can differentiate into mature CMCs and regenerate
the damaged tissue.
In the perspective of cell therapy in patients, it is important
to test whether a similar protocol will also work with human
cells. Human cardiac mesoangioblasts have been isolated
from fragments of vessels inside biopsies of the adult human
heart and their characterization has been reported.
15 Human
cardiac mesoangioblasts were also exposed to SDF-1 and
transfected with L-selectin and, under these conditions,
reached cardiac tissues of infarcted-SCID mice three-fold
more efﬁciently than did their corresponding untreated cells.
Although these data suggest that further work may still be
required to optimize human cardiac mesoangioblasts homing
to the heart, they clearly indicate that the basic homing
mechanisms are similar in mouse and humans and are
equally susceptible to enhancement.
In conclusion, our results suggest that pretreatment
of cardiac mesoangioblasts with SDF-1 and the presence
of L-selectin are required for an efﬁcient intra-vascular
delivery of stem cells to the injured heart. Pretreatment
of stem cells with cytokines is a simple procedure, and
inclusion of a relatively small cDNA in a viral vector is also a
feasible procedure in the context of autologous cell
therapy with engineered stem cells. Taken together, these
strategies represent a novel and simple method for improving
the homing of stem cells to the damaged heart and for
increasing the regeneration area and could be tailored in the
future to different types of stem cells in clinical cell therapy
protocols.
Materials and Methods
Reagents. Anti-GFP Ab was purchased from Chemicon (Temecula, CA, USA).
Anti-av integrins and anti-CD44 Abs were obtained from Serotec (Raleigh, NC,
USA). Most reagents and some Abs were purchased from Sigma (St. Louis, MO,
USA), unless stated otherwise. All the cytokines used were obtained from
Peprotech Inc. (Rocky Hill, NJ, USA). GM1489, the MMP inhibitor, was obtained
fromCalbiochem (EMD BiosciencesInc., Darmstadt, Germany). Alexa-488labeling
kit was from Molecular Probes Inc. (Leiden, The Netherlands). Cav-1 siRNA was
generated and used as described before.
31
C57BL10 WT and SCID-beige mice were purchased from Charles River
Laboratories (Wilmington, MA, USA) and Homo-EGFP mice were obtained from
The Jackson Laboratory (Bar Harbor, ME, USA). All mice were handled following
institutional guidelines.
Cell cultures. Neonatal CMCs were cultured in DMEM plus 20% FBS and
induced to differentiate in DMEM plus 2% FBS. Cardiac mesoangioblasts were
isolated from control or Homo-EGFP male mice and from human ventricle explants,
clonedandexpandedasdescribedpreviously.
14,15Constructshavebeendescribed
previously
13andweretransfectedintomiceorhumancardiacmesoangioblastswith
Lipofectamine (Invitrogen, Carlsbad, CA, USA), and positive clones were selected
by sorting. Human cardiac mesoangioblasts transduced with a lentiviral vector
encoding the GFP protein were used for some in vivo experiments. Murine
microvascular endothelial H5V cells were grown in DMEM plus 10% FBS and
starved for 12h before functional experiments.
Real-time PCR. Total RNA from different organs was isolated with TRIzol
protocol (Invitrogen) and reverse transcribed using the Taqman kit (Platinum Taq
DNA polymerase, Invitrogen). Real-time quantitative PCR was performed on an
Mx3000P real-time PCR system (Stratagene, La Jolla, CA, USA). Each cDNA
sample was ampliﬁed in duplicate using the SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA) for GFP or male y-chromosome detection as double control
(primers GFP: forward, AAGTTCATCTGCACCACCG, reverse, TCCTTGAAGAAG
ATGGTGCG; primers male y chromosome: forward, AAGCGACCCATGAACGCA
TT, reverse, TTCGGGTATTTCTCTCTGTC). Primers for cardiac differentiation
were used as described previously.
14 Data are expressed as the percentage of
migrated cells, which is calculated by comparing the concentration of target gene in
our sample with the total input of injected cells.
Westernblot. Tissuesor GFP-sortedfractionswere homogenized andproteins
extractedandlyseddirectlyinLaemmlibufferonice.Lysateswereresolvedon10%
SDS-PAGE under reducing conditions, and proteins were transferred to
nitrocellulose membrane (Hybond-ECL, Amersham Biosciences, Piscataway, NJ,
USA). Membranes were revealed with anti-GFP, anti-sarcomeric actin and anti-
tubulin Abs.
In vitro transwell migration assay. Transwell ﬁlters of 8-mm thickness
(Corning Incorporated, Acton, MA, USA) were coated with 1% gelatin, and
endothelial H5Vcells (previouslypre-activatedby 12h exposureto TNF-a to induce
the expression of surface antigens and adhesion molecules required for the
appropriate extravasation) were plated to conﬂuence on them for 24h. At the same
time, neonatal CMCs were grown on a p24w plate with a differentiated medium for
0–4 days. In all, 10
4 mice cardiac mesoangioblasts, WT or pretreated (after a dose-
response assay (data not shown), the concentrations used were: 50ng/ml and IL-8
SDF-1;80ng/mlMCP-1;30ng/mlTNF-a;30ng/mlFGF)ortransfected,wereplated
on the upper side of the Transwell chamber 24h after plating H5V cells on the ﬁlter,
and immediately thereafter, the chamber was then moved to wells containing
differentiated CMCs to assay directed migration. After 6h of transmigration,
migrated cardiac mesoangioblasts were counted on the lower side of the ﬁlter. The
results show migrated cells as a percentage of total input cells.
In vivo migration/grafting assay. WT, CAL mice aged 4 months were
injected into the ventricle wall,
32 with 5 10
5 GFP-cardiac mesoangioblasts. After
6, 12 and 24h or 6 weeks, animals were killed and different regions of the heart or
ﬁlter organs were collected. RNA was extracted and a real-time PCR for GFP and
male chromosome as double control(SupplementaryFigure 1) was performedin all
thesamplesasdescribedabove.Dataareexpressedasthepercentageofmigrated
cells, which is calculated by comparing the concentration of target gene in our
sample with the total input of injected cells.
The same samples were also processed for immunohistology against GFP;
brieﬂy, the heart was removed from mice previously injected with cardiac
mesoangioblasts, and the LV free wall and the intraventricular septum and right
ventricle were separated and frozen in liquid N2-cooled isopentane. Serial heart
sections were ﬁxed with 4% PFA, permeabilized and immunostained as described
previously (Galvez et al.) with anti-GFP, anti-laminin or anti-sarcomeric actin Abs.
Alexa-488 or Alexa-594 (Molecular Probes, Eugene, OR, USA) were used as
secondary staining Ig and DAPI for nuclear staining. Images were taken using a
S100 TV microscope (Carl Zeiss MicroImaging Inc., Thornwood, NY, USA).
Echocardiography. Mice were anesthetized by inhalation of isoﬂurane/
oxygen (1.25%/98.75%) and examined by a 30MHz transthoracic
echocardiography probe. Images were obtained with Vevo 770 (VisualSonics,
Toronto, Canada) from mice 2 months after injection. Short-axis and long-axis,
BMode and 2D M-mode views were recorded for off-line analysis. From these
images, LV function was estimated by three validated methods as the SF,
calculated as recommended by the American Society of Echocardiography
33,34 and
ejection fraction (EFm) obtained from the M mode, quantitative ejection fraction
measured from the B mode (EFb) and visual assessment from the B mode by an
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Cell Death and Differentiationexpert in echocardiography in a blind manner. Diastolic and systolic manual
segmentations of the LV endocardial edge in four-chamber views of the heart were
also measured. All data after analysis have been represented in a summary table
(Table 1; LVIDd: LV diastolic diameter; EF: ejection fraction; FS: fractional
shortening; LVAWThd: LV anterior wall diastolic thickness).
Prospective isolation. Control and injected hearts were ﬁnely minced and
digestedwithcollagenase/dispase(Sigma)digestion(0.8IU/mgfor30minat371C).
The cell suspension was ﬁltered to remove tissue debris. Isolated cells were
harvested and resuspended in 1ml of ﬂow sort solution containing 5mg/ml
propidium iodide (Sigma) in PBS (Gibco Brl, Carlsbad, CA, USA). Cells were sorted
for GFP (FL1) and PI (FL3) and collected for further experiments.
Microarray analysis. For mRNA analysis, total RNA was extracted from
treated cardiac mesoangioblasts using TRIzol (Invitrogen Life Technologies,
Carlsbad, CA, USA). cDNA was prepared by reverse transcription reaction and
hybridized to the GEArray gene expression array MM-010 for extracellular matrix
and adhesionmolecules (SuperArray Bioscience Corporation, Frederick, MD, USA)
according to the manufacturer’s instruction. Data were subjected to densitometric
analysis using GEArray Expression Analysis Suite (SuperArray Bioscience
Corporation). RNA levels were expressed as the relative density after normalizing
the hybridization signal to b-actin. The protein expression of positive candidate
genes was conﬁrmed by western blot (data not shown).
Cytokines measurements. Supernatants from ﬁbroblast or CMC cultures
were collected after 4 days of culture and analyzed using the mouse multi-cytokine
detection system from Millipore (Billerica, MA, USA) for measuring cytokines
according to the manufacturer’s instructions. the Hearts from different animal
models were homogenized in cell lysis buffer containing 0.1% igepal, and total
protein concentration was determined using a DC protein assay kit and
spectrophotometer (Bio-Rad). All heart samples were diluted with cell lysis buffer
as required to a ﬁnal total protein concentration of 500g/ml and cytokines were
measured using the same kit protocol as for supernatants. Concentration of
cytokines is represented in pg/ml for supernatants values and in pg/mg for tissue
total protein values.
Statistical analysis. Statistical signiﬁcance of the differences between the
percentages values was assessed using the Kruskal–Wallis one-way ANOVA rank
test. The a-value represents signiﬁcance.
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